---
title: "Correction: Image replacement and data notes for niosomal cisplatin–vorinostat formulation"
id: "plos-one-19-correction-development-of-niosomal-nanoparticles-loaded-with-cisplatin-and"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-19-correction-development-of-niosomal-nanoparticles-loaded-with-cisplatin-and"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0363017"
published_at: "2026-11-18T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Correction: Image replacement and data notes for niosomal cisplatin–vorinostat formulation
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-19-correction-development-of-niosomal-nanoparticles-loaded-with-cisplatin-and
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0363017)
- **Published At:** 2026-11-18T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- A formal correction was published for the PLOS ONE article by Ali, Lafi, and Shalan regarding a duplicated panel in **Fig 4**; the incorrect panel (4C) overlapped with an image from a separate 2025 publication. - The journal posted a corrected version of **Fig 4** and provided underlying image data as S1 File; the supporting file contains the original data underlying the corrected panel. - Investigators reported that the quantified results presented in **Fig 4**—including size, surface charge, morphology, and stability metrics for the niosomal formulation—are not affected by the image duplication. - The corrected figure captions describe a narrow size distribution centered around ~150 nm, a **zeta potential** near −10 mV, TEM morphology (panel C), and a 60-day stability profile at 4°C showing consistent **hydrodynamic diameter** and zeta potential. - The correction notice states the originally published Fig 4C included material from an Elsevier 2025 article that is not covered by the PLOS CC BY license; that material was therefore excluded and replaced in the corrected figure. - The correction provides explicit links to download the corrected figure images (PNG/TIFF) and to the S1 File that contains the original image data for Fig 4C. - The notice does not provide additional experimental details (for example, preparation parameters, drug loading efficiencies, exact particle counts, or analytical methods beyond what is shown in the figure caption); those details were not reported in the correction notice itself. - Readers are pointed to the original article (Development of niosomal nanoparticles loaded with cisplatin and vorinostat combination for cancer therapy) for full experimental context, and to the cited 2025 Elsevier paper for the source of the duplicated image. - The correction clarifies licensing: the reused image originated from a non-CC BY source and therefore had to be excluded from the PLOS license for the corrected record. - The correction ends with data availability notes and provides DOI, figure download links, and the S1 File as the repository of the original image supporting the corrected panel.
## Clinical Analysis & Structured Key Points
Correction: Development of niosomal nanoparticles loaded with cisplatin and vorinostat combination for cancer therapy | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Metrics Comments Media Coverage Reader Comments Figures Figures Fig 4C in this article [ 1 ] is incorrect and overlaps with Fig 3D in [ 2 ]. The corrected Fig 4 is provided with this notice, and the image data provided in support of this figure are in S1 File . The corresponding author stated that the quantified results in Fig 4 are not affected by the above error. Fig 4C in [ 1 ] reports material from [ 2 ], published in 2025 by Elsevier, which is not offered under a CC BY license and is therefore excluded from this article’s [ 1 ] license. Download: PNG larger image TIFF original image Fig 4. Characterization and Stability of Niosomal Formulation Encapsulating Cisplatin and Vorinostat (NIO-CIS-VOR). (A) Size distribution by intensity showing a narrow peak around ~150 nm, indicating uniform particle size. (B) Zeta potential distribution demonstrating surface charge stability with values near −10 mV. (C) Presents TEM morphology. (D) Stability profile at 4°C over 60 days, showing consistent hydrodynamic diameter (blue) and zeta potential (red), indicating good physical stability of the formulation. https://doi.org/10.1371/journal.pone.0363017.g004 Supporting information S1 File. Original data underlying Fig 4C. https://doi.org/10.1371/journal.pone.0363017.s001 (TIF) References 1. Ali H, Lafi Z, Shalan N. Development of niosomal nanoparticles loaded with cisplatin and vorinostat combination for cancer therapy. PLoS One. 2026;21(2):e0342344. pmid:41650115 View Article PubMed/NCBI Google Scholar 2. Alrubaye MA, Lafi Z, Abu Hajleh MN, Abuamara TMM, Mehdawi A. Co-encapsulation of coumarin and Q10 into solid lipid nanoparticles for wound healing. J Drug Delivery Sci Technol. 2025;105:106645. View Article Google Scholar Citation: Ali H, Lafi Z, Shalan N (2026) Correction: Development of niosomal nanoparticles loaded with cisplatin and vorinostat combination for cancer therapy. PLoS One 21(11): e0363017. https://doi.org/10.1371/journal.pone.0363017 Published: November 18, 2026 Copyright: © 2026 Ali et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Download PDF Citation XML Print Share Reddit Facebook LinkedIn Mendeley Bluesky Email Related PLOS Articles CORRECTION pertains to Development of niosomal nanoparticles loaded with cisplatin and vorinostat combination for cancer therapy View Page PDF Advertisement
## Related Clinical Research

- [Nelfinavir enhances cisplatin-induced immunogenic cell death in ovarian cancer cells](https://medichelpline.com/clinical-feed/biorxiv-6-combined-nelfinavir-and-cisplatin-treatment-promotes-inflammatory-signaling-and.md)
- [Cobalt‑group metal complexes as anticancer agents: how ligands shape activity](https://medichelpline.com/clinical-feed/pubmed-42929697.md) (DOI: 10.1039/d6dt00899b)
- [Sex Differences in ICI Survival for Advanced NSCLC: Meta-analysis Findings](https://medichelpline.com/clinical-feed/plos-one-15-sex-difference-in-survival-benefits-of-immune-checkpoint-inhibitors-in-advanced.md)
- [Enfortumab vedotin shows increased activity in cisplatin‑resistant HT1376 bladder cancer model](https://medichelpline.com/clinical-feed/plos-one-20-enhanced-enfortumab-vedotin-sensitivity-in-a-cisplatin-resistant-bladder-cancer.md)
- [HPV oncogenes shift DNA crosslink repair toward a PRIMPOL-dependent vulnerability](https://medichelpline.com/clinical-feed/biorxiv-6-hpv-oncogenes-rewire-dna-crosslink-repair-to-create-a-primpol-dependent.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.